NCT01227889 2017-10-04A Study Comparing GSK2118436 to Dacarbazine (DTIC) in Previously Untreated Subjects With BRAF Mutation Positive Advanced (Stage III) or Metastatic (Stage IV) MelanomaGlaxoSmithKlinePhase 3 Completed251 enrolled 21 charts